The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 501–600 of 999
Gustiananda, M., Sulistyo, B. P., Agustriawan, D., & Andarini, S. (2021) · Vaccines · doi:10.3390/vaccines9121459 · Cited by 27
Steiner, S., Schwarz, T., Corman, V. M., Gebert, L., Kleinschmidt, M. C., Wald, A., Gläser, S., Kruse, J. M., Zickler, D., Peric, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840126 · Cited by 24
Self-citationJantarabenjakul, W., Sodsai, P., Chantasrisawad, N., Jitsatja, A., Ninwattana, S., Thippamom, N., Ruenjaiman, V., Tan, C. W., Pradit, R., Sophonphan, J., et al. (2022) · Vaccines · doi:10.3390/vaccines10050639 · Cited by 24
SARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 23
Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection
Lavell, A. H. A., Sikkens, J. J., Edridge, A. W. D., van der Straten, K., Sechan, F., Oomen, M., Buis, D. T. P., Schinkel, M., Burger, J. A., Poniman, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105105 · Cited by 25
Maghsood, F., Vanan, A. G., Yadegari, H., Golsaz‐Shirazi, F., Amiri, M. M., & Shokri, F. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2431 · Cited by 25
Jackson-Thompson, B. M., Goguet, E., Laing, E. D., Olsen, C. H., Pollett, S. D., Hollis-Perry, M., Maiolatesi, S. E., Illinik, L., Ramsey, K. F., Reyes, A. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06233-1 · Cited by 23
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Su, S.-C., Yang, T., Yu, P., Liang, K.-H., Wy, C., Yang, C.-W., Lin, H.-T., Wang, M.-J. S., Lu, R., Tso, H.-C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009704 · Cited by 24
Polak, K., Greze, N., Lachat, M., Merle, D., Chiumento, S., Bertrand‐Gaday, C., Trentin, B., & Mamoun, R. Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.28.357137 · Cited by 24
Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown
Zrzavy, T., Wimmer, I., Rommer, P. S., & Berger, T. (2020) · European Journal of Neurology · doi:10.1111/ene.14578 · Cited by 23
Ong, E., Huang, X., Pearce, R., Zhang, Y., & He, Y. O. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.039 · Cited by 24
Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
Pawelec, G., & McElhaney, J. E. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00219-y · Cited by 23
Santiago, L., Uranga-Murillo, I., Arias, M. A., González‐Ramírez, A. M., Macías‐León, J., Moreo, E., Redrado, S., García‐García, A., Taleb, V., Lira‐Navarrete, E., et al. (2021) · Biology · doi:10.3390/biology10030208 · Cited by 23
Levite, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.617658 · Cited by 23
Immunity after SARS-CoV-2 infections
Jagannathan, P., & Wang, T. T. (2021) · Nature Immunology · doi:10.1038/s41590-021-00923-3 · Cited by 22
Liu, R., Jiang, W., & Mellins, E. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00717-5 · Cited by 22
Chu, C.-F., Sabath, F., Fibi-Smetana, S., Sun, S., Öllinger, R., Noeßner, E., Chao, Y.-Y., Rinke, L., Winheim, E., Rad, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.601080 · Cited by 23
Racine‐Brzostek, S., Yee, J. K., Sukhu, A. C., Qiu, Y., Rand, S., Barone, P. D., Hao, Y., Yang, H. S., Meng, Q. H., Apple, F. S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151477 · Cited by 25
Immunometabolic Dysregulation at the Intersection of Obesity and COVID-19
Khwatenge, C. N., Pate, M., Miller, L. C., & Sang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.732913 · Cited by 22
HLA‐dependent variation in SARS‐CoV‐2 CD8 + T cell cross‐reactivity with human coronaviruses
Buckley, P. R., Lee, C. H.-J., Pinho, M. P., Babu, R. O., Woo, J., Antanaviciute, A., Simmons, A., Ogg, G. S., & Koohy, H. (2022) · Immunology · doi:10.1111/imm.13451 · Cited by 22
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25
Ojal, J., Brand, S. P. C., Were, V. O., Okiro, E. A., Kombe, I. K., Mburu, C., Aziza, R., Ogero, M. O., Agweyu, A., Warimwe, G. M., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16748.2 · Cited by 23
Mouse models in COVID-19 research: analyzing the adaptive immune response
Clever, S., & Volz, A. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00735-8 · Cited by 26
Sun, S., Li, E., Zhao, G., Tang, J., Zuo, Q., Cai, L., Xu, C., Sui, C., Ou, Y., Liu, C., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121907 · Cited by 22
CD4 + and CD8 + T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
Kar, M., Johnson, K., Vanderheiden, A., Elrod, E. J., Floyd, K. A., Geerling, E., Stone, E. T., Salinas, E., Banakis, S., Wang, W., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp2636 · Cited by 22
Root-Bernstein, R. S. (2021) · Vaccines · doi:10.3390/vaccines9050474 · Cited by 23
Mannar, D., Saville, J. W., Poloni, C., Zhu, X. Q., Bezeruk, A., Tidey, K., Ahmed, S., Tuttle, K. R., Hassani, F. V., CHOLAK, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46104-2 · Cited by 22
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
Vashishtha, V. M., & Kumar, P. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1845524 · Cited by 22
The role of T‐cell immunity in COVID‐19 severity amongst people living with type II diabetes
Tong, Z. W. M., Grant, E. J., Gras, S., Wu, M., Smith, C., Barrett, H. L., Gallo, L. A., & Short, K. R. (2021) · FEBS Journal · doi:10.1111/febs.16105 · Cited by 23
Jung, J., Bong, J.-H., Kim, T. H., Sung, J. S., Lee, C., Kang, M., Kim, H. O., Shin, H., & Pyun, J. (2021) · BioChip Journal · doi:10.1007/s13206-021-00033-0 · Cited by 22
Conway, S. R., Lazarski, C. A., Field, N. E., Jensen-Wachspress, M. A., Lang, H., Kankate, V. V., Durkee-Shock, J. R., Kinoshita, H., Suslovic, W., Webber, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793197 · Cited by 21
Singh, V., Obregon-Perko, V., Lapp, S. A., Horner, A. M., Brooks, A. D., Macoy, L., Hussaini, L., Lu, A., Gibson, T., Silvestri, G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155145 · Cited by 21
Miyara, M., Saichi, M., Sterlin, D., Anna, F., Marot, S., Mathian, A., Atif, M., Quentric, P., Mohr, A., Claër, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790334 · Cited by 23
Aljabr, W. A., Al-Amari, A., Abbas, B., Karkashan, A., Alamri, S. S., Alnamnakani, M., & Alqahtani, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00845-21 · Cited by 27
Dykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Rashid, R., Westlake, T., Zhang, L., Zhang, J., Cheung, L. S., Caushi, J. X., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104048 · Cited by 23
Wieland, T. (2020) · REGION · doi:10.18335/region.v7i2.324 · Cited by 25
Beijnen, E. M. S., & van Haren, S. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607977 · Cited by 22
Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19Preprint
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Swaneveld, F. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.159202 · Cited by 22
Dijkstra, J. M., & Hashimoto, K. (2020) · F1000Research · doi:10.12688/f1000research.23458.1 · Cited by 20
Pinotti, F., Wikramaratna, P. S., Obolski, U., Paton, R. S., Damineli, D. S. C., Alcântara, L. C. J., Giovanetti, M., Gupta, S., & Lourenço, J. (2021) · BMC Medicine · doi:10.1186/s12916-020-01887-1 · Cited by 19
Jo, N., Zhang, R., Ueno, H., Yamamoto, T., Weiskopf, D., Nagao, M., Yamanaka, S., & Hamazaki, Y. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.719342 · Cited by 20
Simnica, D., Schultheiß, C., Mohme, M., Paschold, L., Willscher, E., Fitzek, A., Püschel, K., Matschke, J., Ciesek, S., Sedding, D., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1340 · Cited by 19
Meyer‐Arndt, L., Schwarz, T., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Gürcan, K., Uyar‐Aydin, Z., Müller, M. A., Drosten, C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100990 · Cited by 20
Self-citationLong-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
Sieber, J., Mayer, M., Schmidthaler, K., Kopanja, S., Camp, J. V., Popovitsch, A., Dwivedi, V., Hoz, J., Schoof, A., Weseslindtner, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882456 · Cited by 21
Goyal, A., Duke, E. R., Ojeda, E. F. C., & Schiffer, J. T. (2022) · iScience · doi:10.1016/j.isci.2022.104448 · Cited by 36
Risk of severe COVID-19 infection among adults with prior exposure to children
Solomon, M. D., Escobar, G. J., Lu, Y., Schlessinger, D., Steinman, J. B., Steinman, L., Lee, C., & Liu, V. X. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204141119 · Cited by 22
Karsten, H., Cords, L., Westphal, T., Knapp, M., Brehm, T. T., Hermanussen, L., Omansen, T. F., Schmiedel, S., Woost, R., Ditt, V., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1410 · Cited by 21
Iavarone, M. A., Tosetti, G., Facchetti, F., Topa, M., Lim, J. M. E., Hang, S. K., Licari, D., Lombardi, A., D’Ambrosio, R., Degasperi, E., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.09.010 · Cited by 20
Yang, G., Wang, J., Sun, P., Qin, J., Yang, X., Chen, D., Zhang, Y., Zhong, N. S., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146196 · Cited by 23
Livieratos, A., Gogos, C. A., & Akinosoglou, K. (2024) · Viruses · doi:10.3390/v16050685 · Cited by 23
Corse, T. D., Dayan, L. S., Kersten, S., Battaglia, F., Terlecky, S. R., & Han, Z. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.50537 · Cited by 21
Zelba, H., Worbs, D., Harter, J., Pieper, N., Kyzirakos, C., Kayser, S., Seibold, M., Bartsch, O., Ködding, J., & Biskup, S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000811 · Cited by 21
A possible role for GRP78 in cross vaccination against COVID-19
Elfiky, A. A., Ibrahim, I. M., Ismail, A. M., & Elshemey, W. M. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.004 · Cited by 21
Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21
Adaptive immunity to human coronaviruses is widespread but low in magnitude
Tan, H., Lee, W. S., Wragg, K. M., Nelson, C., Esterbauer, R., Kelly, H. G., Amarasena, T. H., Jones, R. M., Starkey, G., Wang, B. Z., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1264 · Cited by 18
Immune response to COVID-19 in older adults
Jergović, M., Coplen, C. P., Uhrlaub, J. L., & Nikolich‐Žugich, J. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.017 · Cited by 20
Phenotypes and Functions of SARS-CoV-2-Reactive T Cells
Jung, M. K., & Shin, E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0079 · Cited by 19
COVID-19: an ‘extraterrestrial’ disease?
Paul, É., Brown, G. W., Dechamps, M., Kalk, A., Laterre, P., Rentier, B., Ridde, V., & Zizi, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.051 · Cited by 20
Hussain, A., Rafeeq, H., Asif, H. M., Shabbir, S., Bilal, M., Mulla, S. I., Franco, M., & Iqbal, H. M. N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108050 · Cited by 20
Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria
Eggenhuizen, P. J., Ng, B. H., Chang, J., Cheong, R. M. Y., Yellapragada, A., Wong, W. Y., Ting, Y. T., Monk, J. A., Gan, P., Holdsworth, S. R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821595 · Cited by 20
Peter, L., Wendering, D. J., Schlickeiser, S., Hoffmann, H., Noster, R., Wagner, D. L., Zarrinrad, G., Münch, S., Picht, S., Schulenberg, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.012 · Cited by 19
Xiao, C., Mao, L., Wang, Z., Gao, L., Zhu, G., Su, J., Chen, X., Yuan, J., Hu, Y., Yin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103934 · Cited by 21
Mohamed, Y., El‐Maradny, Y. A., Saleh, A. K., Nayl, A. A., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113499 · Cited by 20
Long-Term Antibody Response to SARS-CoV-2 in Children
Dunay, G. A., Barroso, M., Woidy, M., Danecka, M. K., Engels, G., Hermann, K., Neumann, F. S., Paul, K., Beime, J., Escherich, G., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01355-w · Cited by 24
Wang, C., Yang, S., Duan, L., Du, X., Tao, J., Wang, Y., Yang, J., Lv, Y., Li, J., Zhang, C., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01957-1 · Cited by 19
Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Tauzin, A., Painter, M. M., Goel, R. R., Laporte, M., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105904 · Cited by 20
Metabolic dysregulation impairs lymphocyte function during severe SARS-CoV-2 infection
Gurshaney, S., Alvarez, A. M., Ezhakunnel, K., Manalo, A., Huynh, T.-H., Abe, J., Le, N.-T., Weiskopf, D., Sette, A., Lupu, D. S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04730-4 · Cited by 23
Tada, T., Peng, J.-Y., Dcosta, B. M., & Landau, N. R. (2023) · JCI Insight · doi:10.1172/jci.insight.167306 · Cited by 20
COVID-19 and Multiorgan Response: The Long-Term Impact
Harky, A., Ala'Aldeen, A., Butt, S., Duric, B., Roy, S., & Zeinah, M. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101756 · Cited by 21
Sałkowska, A., Karwaciak, I., Karaś, K., Dastych, J., & Ratajewski, M. (2020) · Vaccines · doi:10.3390/vaccines8040673 · Cited by 21
Identification of VIMP as a Gene Inhibiting Cytokine Production in Human CD4+ Effector T Cells
Capelle, C., Zeng, N., Danileviciute, E., Rodrigues, S. F., Ollert, M. W., Balling, R., & HeFeng, F. Q. (2020) · iScience · doi:10.1016/j.isci.2021.102289 · Cited by 21
SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals
Rha, M., Kim, A. R., & Shin, E. (2021) · Immune Network · doi:10.4110/in.2021.21.e2 · Cited by 20
Functional SARS-CoV-2-sperific immune memory persists after mild COVID-19Preprint
Rodda, L., Netland, J., Shehata, L., Pruner, K., Morawski, P., Thouvenel, C., Takehara, K., Eggenberger, J., Hemann, E. A., Waterman, H., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-57112/v1 · Cited by 237
Mahmood, Z., Alrefai, H., Hetta, H. F., Kader, H. A., Munawar, N., Rahman, S. A., Elshaer, S., Batiha, G. E., & Muhammad, K. (2020) · Vaccines · doi:10.3390/vaccines8030443 · Cited by 20
Hempel, L., Piehler, A. P., Pfaffl, M. W., Molnar, J., Kirchner, B., Robert, S., Veloso, J., Gandorfer, B., Trepotec, Ž., Mederle, S., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3435 · Cited by 19
Diagnostic testing for SARS-CoV-2/COVID19
Spearman, P. W. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000972 · Cited by 21
Hubiche, T., Phan, A., Leducq, S., Rapp, J., Fertitta, L., Aubert, H., Barbarot, S., Chiavérini, C., Giraudeau, B., Lasek, A., et al. (2021) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2020.11.005 · Cited by 19
SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
Fernández‐Ruiz, M., Olea, B., Giménez, E., Laguna‐Goya, R., Trujillo, H., Caravaca‐Fontán, F., Gutiérrez, E., López‐Medrano, F., Remigia, M. J., Almendro-Vázquez, P., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003672 · Cited by 18
Renner, K., Schwittay, T., Chaabane, S., Gottschling, J., Müller, C., Tiefenböck, C., Salewski, J.-N., Winter, F., Buchtler, S., Balam, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23334-2 · Cited by 23
Angelis, M. L. D., Francescangeli, F., Rossi, R., Giuliani, A., Maria, R. D., & Zeuner, A. (2021) · Viruses · doi:10.3390/v13060961 · Cited by 17
Wong, L.-Y. R., Zheng, J. H., Sariol, A., Lowery, S. A., Meyerholz, D. K., Gallagher, T., & Perlman, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102983118 · Cited by 24
Qiu, X., Hua, X., Li, Q., Zhou, Q., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774776 · Cited by 19
Risk factors of the severe course and fatal outcome in COVID-19
Sсherbak, S. G., Kamilova, Т. A., Голота, А. С., & Vologzhanin, D. A. (2022) · Physical and rehabilitation medicine medical rehabilitation · doi:10.36425/rehab104997 · Cited by 22
An efficient immunoassay for the B cell help function of SARS-CoV-2-specific memory CD4+ T cells
Ansari, A., Sachan, S., Jit, B. P., Sharma, A. K., Coshic, P., Sette, A., Weiskopf, D., & Gupta, N. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100224 · Cited by 19
The deciphering of the immune cells and marker signature in COVID‐19 pathogenesis: An update
Jasim, S. A., Mahdi, R. S., Bokov, D. O., Najm, M. A. A., Sobirova, G. N., Bafoeva, Z. O., Taifi, A., Alkadir, O. K. A., Mustafa, Y. F., Mirzaei, R., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28000 · Cited by 21
Andreica, I., Blazquez‐Navarro, A., Sokolar, J., Anft, M., Kiltz, U., Pfaender, S., Blanco, E. V., Westhoff, T. H., Babel, N., Stervbo, U., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002293 · Cited by 19
The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro
Lyu, J., Bao, L., Shen, X., Yan, C., Zhang, C., Wei, W., Yang, Y., Li, J., Dong, J., Xiao, L., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107797 · Cited by 20
Ma, T., Ryu, H., McGregor, M. M., Babcock, B. R., Neidleman, J. A., Xie, G., George, A. F., Frouard, J., Murray, V., Gill, G., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100465 · Cited by 19
Jing, L., Wu, X., Krist, M. P., Hsiang, T.-Y., Campbell, V. L., McClurkan, C. L., Favors, S. M., Hemingway, L. A., Godornes, C., Tong, D. Q., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158126 · Cited by 18
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 26
Schmidt, K. G., Nganou‐Makamdop, K., Tenbusch, M., Kenz, B. E., Maier, C., Lapuente, D., Überla, K., Spriewald, B. M., Bergmann, S., Harrer, E. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627568 · Cited by 18
Ojal, J., Brand, S. P. C., Were, V. O., Okiro, E. A., Kombe, I. K., Mburu, C., Aziza, R., Ogero, M. O., Agweyu, A., Warimwe, G. M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16748.1 · Cited by 29
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
Woopen, C., Schleußner, K., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701752 · Cited by 20
Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity
Schetelig, J., Heidenreich, F., Baldauf, H., Trost, S., Falk, B., Hoßbach, C., Real, R. G. L., Roers, A., Lindemann, D., Dalpke, A. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698193 · Cited by 18
Uranga-Murillo, I., Morte-Romea, E., Hidalgo, S., Pesini, C., García‐Mulero, S., Sierra-Monzón, J. L., Santiago, L., Arias, M. A., de Miguel, D., Encabo-Berzosa, M. D. M., et al. (2021) · Theranostics · doi:10.7150/thno.63463 · Cited by 20
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 18
Fahrner, J., Lahmar, I., Goubet, A., Haddad, Y., Carrier, A., Mazzenga, M., Drubay, D., Silva, C. A. C., Lyon COVID Study Group, de Sousa, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1441 · Cited by 20
Gatti, L., Koenen, M. H., Zhang, J. D., Anisimova, M. O., Verhagen, L. M., Schutten, M., Osterhaus, A. D. M. E., & van der Vries, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-08233-w · Cited by 17
Teglgaard, R. S., MacPherson, C. R., Zucco, A. G., Agius, R., Faitová, T., Andersen, M. A., da Cunha‐Bang, C., Gjærde, L. K., Møller, M. E. E., Brooks, P. T., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00178-5 · Cited by 19
Self-citation
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
